Eyenuk
Latest round
- Series A
Last raised
- Aug 2022
Total raised
- $22M
Investors
- 5
About Eyenuk
Eyenuk, Inc.Founded in 2010 by Kaushal Solanki, Eyenuk, Inc. is based in Woodland Hills, US, with a focus on leveraging artificial intelligence for medical diagnostics.Eyenuk, Inc. specializes in artificial intelligence-driven medical technologies, primarily centered around its flagship product, the EyeArt® AI Eye Screening System. This system offers autonomous detection of diabetic retinopathy, a leading cause of vision loss, by analyzing retinal images to identify disease indicators swiftly and accurately. The EyeArt system functions without the need for expert human grading or eye dilation, allowing for comprehensive imaging, grading, and reporting within a single office visit. The technology has been validated extensively, having been tested on over half a million patient visits globally, and it has received multiple regulatory approvals, including US FDA clearance and CE marking as a class IIb medical device in the European Union. Eyenuk primarily targets healthcare providers, including general practitioners, endocrinologists, ophthalmologists, and optometrists, allowing them to offer efficient diabetic retinopathy screenings directly in their clinics.Eyenuk generates revenue through partnerships and direct sales of its AI Eye Screening technologies, particularly the EyeArt® system, which is a critical component of its business model. The company establishes relationships with healthcare providers who utilize its product in clinical workflows, facilitating improved patient compliance and streamlined screening processes. Revenue transactions typically involve the sale of the EyeArt system, potentially paired with service agreements that may include software updates and support. While specific pricing details for the EyeArt system are not disclosed, the company's transaction structure suggests that healthcare facilities may engage in long-term partnerships with Eyenuk, integrating their AI screening solutions into regular patient care protocols. The company aims to expand its market presence, particularly in regions such as Europe and Canada, where the demand for AI-driven healthcare solutions is on the rise. Eyenuk is committed to introducing new advancements to its EyeArt® system, targeting a release within the next few years.
Who invested in Eyenuk
5 investors across 1 round
See all investors in Eyenuk
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 3, 2022
Amount
$22M
Investors
Questions about Eyenuk
Who invested in Eyenuk?
Eyenuk has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Eyenuk raised?
Eyenuk has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Eyenuk last raise money?
Eyenuk's most recent round on record is a Series A, in Aug 2022.
What does Eyenuk do?
Eyenuk is a medical devices & equipment company.
Where is Eyenuk headquartered?
Eyenuk is headquartered in Woodland Hills, US.
Which VCs invest in companies like Eyenuk?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back medical devices & equipment companies at Eyenuk's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series A
Raising like Eyenuk? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.